Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages
Filter by Categories
15th National Conference of the IAOMFP, Chennai, 2006
Abstract
Abstracts from current literature
Acne in India: Guidelines for management - IAA Consensus Document
Addendum
Announcement
Art & Psychiatry
Article
Articles
Association Activities
Association Notes
Award Article
Book Review
Brief Report
Case Analysis
Case Letter
Case Letters
Case Notes
Case Report
Case Reports
Clinical and Laboratory Investigations
Clinical Article
Clinical Studies
Clinical Study
Commentary
Conference Oration
Conference Summary
Continuing Medical Education
Correspondence
Corrigendum
Cosmetic Dermatology
Cosmetology
Current Best Evidence
Current Issue
Current View
Derma Quest
Dermato Surgery
Dermatopathology
Dermatosurgery Specials
Dispensing Pearl
Do you know?
Drug Dialogues
e-IJDVL
Editor Speaks
Editorial
Editorial Remarks
Editorial Report
Editorial Report - 2007
Editorial report for 2004-2005
Errata
Erratum
Focus
Fourth All India Conference Programme
From Our Book Shelf
From the Desk of Chief Editor
General
Get Set for Net
Get set for the net
Guest Article
Guest Editorial
History
How I Manage?
IADVL Announcement
IADVL Announcements
IJDVL Awards
IJDVL AWARDS 2015
IJDVL Awards 2018
IJDVL Awards 2019
IJDVL Awards 2020
IJDVL International Awards 2018
Images in Clinical Practice
Images in Dermatology
In Memorium
Inaugural Address
Index
Knowledge From World Contemporaries
Leprosy Section
Letter in Response to Previous Publication
Letter to Editor
Letter to the Editor
Letter to the Editor - Case Letter
Letter to the Editor - Letter in Response to Published Article
LETTER TO THE EDITOR - LETTERS IN RESPONSE TO PUBLISHED ARTICLES
Letter to the Editor - Observation Letter
Letter to the Editor - Study Letter
Letter to the Editor - Therapy Letter
Letter to the Editor: Articles in Response to Previously Published Articles
Letters in Response to Previous Publication
Letters to the Editor
Letters to the Editor - Letter in Response to Previously Published Articles
Letters to the Editor: Case Letters
Letters to the Editor: Letters in Response to Previously Published Articles
Media and news
Medicolegal Window
Messages
Miscellaneous Letter
Musings
Net Case
Net case report
Net Image
Net Images
Net Letter
Net Quiz
Net Study
New Preparations
News
News & Views
Obituary
Observation Letter
Observation Letters
Oration
Original Article
ORIGINAL CONTRIBUTION
Original Contributions
Pattern of Skin Diseases
Pearls
Pediatric Dermatology
Pediatric Rounds
Perspective
Presedential Address
Presidential Address
Presidents Remarks
Quiz
Recommendations
Regret
Report
Report of chief editor
Report of Hon : Treasurer IADVL
Report of Hon. General Secretary IADVL
Research Methdology
Research Methodology
Resident page
Resident's Page
Resident’s Page
Residents' Corner
Residents' Corner
Residents' Page
Retraction
Review
Review Article
Review Articles
Reviewers 2022
Revision Corner
Self Assessment Programme
SEMINAR
Seminar: Chronic Arsenicosis in India
Seminar: HIV Infection
Short Communication
Short Communications
Short Report
Snippets
Special Article
Specialty Interface
Studies
Study Letter
Study Letters
Supplement-Photoprotection
Supplement-Psoriasis
Symposium - Contact Dermatitis
Symposium - Lasers
Symposium - Pediatric Dermatoses
Symposium - Psoriasis
Symposium - Vesicobullous Disorders
SYMPOSIUM - VITILIGO
Symposium Aesthetic Surgery
Symposium Dermatopathology
Symposium-Hair Disorders
Symposium-Nails Part I
Symposium-Nails-Part II
Systematic Review and Meta-Analysis
Systematic Reviews and Meta-analyses
Systematic Reviews and Meta-analysis
Tables
Technology
Therapeutic Guideline-IADVL
Therapeutic Guidelines
Therapeutic Guidelines - IADVL
Therapeutics
Therapy
Therapy Letter
Therapy Letters
View Point
Viewpoint
What’s new in Dermatology
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages
Filter by Categories
15th National Conference of the IAOMFP, Chennai, 2006
Abstract
Abstracts from current literature
Acne in India: Guidelines for management - IAA Consensus Document
Addendum
Announcement
Art & Psychiatry
Article
Articles
Association Activities
Association Notes
Award Article
Book Review
Brief Report
Case Analysis
Case Letter
Case Letters
Case Notes
Case Report
Case Reports
Clinical and Laboratory Investigations
Clinical Article
Clinical Studies
Clinical Study
Commentary
Conference Oration
Conference Summary
Continuing Medical Education
Correspondence
Corrigendum
Cosmetic Dermatology
Cosmetology
Current Best Evidence
Current Issue
Current View
Derma Quest
Dermato Surgery
Dermatopathology
Dermatosurgery Specials
Dispensing Pearl
Do you know?
Drug Dialogues
e-IJDVL
Editor Speaks
Editorial
Editorial Remarks
Editorial Report
Editorial Report - 2007
Editorial report for 2004-2005
Errata
Erratum
Focus
Fourth All India Conference Programme
From Our Book Shelf
From the Desk of Chief Editor
General
Get Set for Net
Get set for the net
Guest Article
Guest Editorial
History
How I Manage?
IADVL Announcement
IADVL Announcements
IJDVL Awards
IJDVL AWARDS 2015
IJDVL Awards 2018
IJDVL Awards 2019
IJDVL Awards 2020
IJDVL International Awards 2018
Images in Clinical Practice
Images in Dermatology
In Memorium
Inaugural Address
Index
Knowledge From World Contemporaries
Leprosy Section
Letter in Response to Previous Publication
Letter to Editor
Letter to the Editor
Letter to the Editor - Case Letter
Letter to the Editor - Letter in Response to Published Article
LETTER TO THE EDITOR - LETTERS IN RESPONSE TO PUBLISHED ARTICLES
Letter to the Editor - Observation Letter
Letter to the Editor - Study Letter
Letter to the Editor - Therapy Letter
Letter to the Editor: Articles in Response to Previously Published Articles
Letters in Response to Previous Publication
Letters to the Editor
Letters to the Editor - Letter in Response to Previously Published Articles
Letters to the Editor: Case Letters
Letters to the Editor: Letters in Response to Previously Published Articles
Media and news
Medicolegal Window
Messages
Miscellaneous Letter
Musings
Net Case
Net case report
Net Image
Net Images
Net Letter
Net Quiz
Net Study
New Preparations
News
News & Views
Obituary
Observation Letter
Observation Letters
Oration
Original Article
ORIGINAL CONTRIBUTION
Original Contributions
Pattern of Skin Diseases
Pearls
Pediatric Dermatology
Pediatric Rounds
Perspective
Presedential Address
Presidential Address
Presidents Remarks
Quiz
Recommendations
Regret
Report
Report of chief editor
Report of Hon : Treasurer IADVL
Report of Hon. General Secretary IADVL
Research Methdology
Research Methodology
Resident page
Resident's Page
Resident’s Page
Residents' Corner
Residents' Corner
Residents' Page
Retraction
Review
Review Article
Review Articles
Reviewers 2022
Revision Corner
Self Assessment Programme
SEMINAR
Seminar: Chronic Arsenicosis in India
Seminar: HIV Infection
Short Communication
Short Communications
Short Report
Snippets
Special Article
Specialty Interface
Studies
Study Letter
Study Letters
Supplement-Photoprotection
Supplement-Psoriasis
Symposium - Contact Dermatitis
Symposium - Lasers
Symposium - Pediatric Dermatoses
Symposium - Psoriasis
Symposium - Vesicobullous Disorders
SYMPOSIUM - VITILIGO
Symposium Aesthetic Surgery
Symposium Dermatopathology
Symposium-Hair Disorders
Symposium-Nails Part I
Symposium-Nails-Part II
Systematic Review and Meta-Analysis
Systematic Reviews and Meta-analyses
Systematic Reviews and Meta-analysis
Tables
Technology
Therapeutic Guideline-IADVL
Therapeutic Guidelines
Therapeutic Guidelines - IADVL
Therapeutics
Therapy
Therapy Letter
Therapy Letters
View Point
Viewpoint
What’s new in Dermatology
View/Download PDF

Translate this page into:

Net Letter
ARTICLE IN PRESS
doi:
10.25259/IJDVL_678_2023

Clinical features, laboratory tests and risk factors in patients with erythrodermic psoriasis complicated with systemic infection: A retrospective study

Department of Dermatology, Affiliated Hospital of Xuzhou Medical University, Quanshan, Xuzhou, China.

Corresponding author: Dr. Guan Jiang, Department of Dermatology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China. dr.guanjiang@xzhmu.edu.cn

Licence
This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License, which allows others to remix, transform, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

How to cite this article: Sun D, Zhang Y, Jiang G. Clinical features, laboratory tests and risk factors in patients with erythrodermic psoriasis complicated with systemic infection: A retrospective study. Indian J Dermatol Venereol Leprol. doi: 10.25259/IJDVL_678_2023

Dear Editor,

Psoriasis is a chronic inflammatory dermatosis with immune-mediated polygenic defects. Erythrodermic psoriasis (EP) is one of its severe variants which is not uncommon in Asian populations1 and has a high mortality rate.2 Recently, several authors have highlighted the important role of infections in its occurrence and development. However, few studies exist to identify the risk-factors associated with infection in these patients, especially studies targeting severe EP, clinical features, and laboratory markers associated with infection. This project investigated clinical features, laboratory tests, and related factors of EP patients with systemic infections by retrospectively analysing their medical records, which were retrieved from the Affiliated Hospital of Xuzhou Medical University. The probability of EP patients merging with infections is high and types are diverse. Joint pain/pustules, smoking history, hyperglycemia, and hypoproteinemia are related factors for EP combined with infection. C-reactive protein, systemic immune inflammation index, α-1 acidic glycoprotein, N-terminal B-type natriuretic peptidogen, albumin, cholinesterase, and total cholesterol are new indicators for diagnosing EP with infection, and the regression predicted values performs better.

The hospital information system (HIS) of the Department of Dermatology of the Affiliated Hospital of Xuzhou Medical University was searched and all relevant medical records for EP were reviewed from January 2012 to December 2022. Finally, we included 105 inpatients with EP and concomitant infection in our study. Our study has been approved by the Medical Ethics Committee of Xuzhou Medical University Affiliated Hospital with opinion number XYFY2022-KL454-01.

This study used retrospective analysis methods to collect data from all included patients, including basic demography, clinical characteristics, and laboratory findings. We included the results of the first test only in patients who underwent multiple tests for the same item. All data was organised for statistical analysis using Software SPSS26.0.

Chi-square test, continuous corrected chi-square test, independent sample t-test, corrected t-test, Mann–Whitney U test, and unconditional logistic regression were used. The test level α was defined as 0.05 and P<0.05 was considered statistically different and P<0.01 was considered to be significantly different in the distribution between both groups. Receiver Operating Characteristic (ROC) curve was analysed and drawn by the software GraphPad Prism 9.

Excluding 32 suspected infections, 105 hospitalised patients with EP were finally included in this study with a total of 62 patients with systemic infection and 43 patients without systemic infection with an overall infection rate of 45.3%. Various types of infections may complicate EP, respiratory infections being the most frequent [Table 1].

Table 1: Patients with erythrodermic psoriasis and systemic infection.
Type/pathogen Number Scale % (n=62)
Bloodstream infections 12 19.4
Skin infections 7 11.3
Respiratory infections 26 41.9
Hepatitis 3 4.8
Tuberculosis 2 3.2
Urinary tract infections 9 14.5
Periodontitis 1 1.6
Gastroenteritis 2 3.2
Co-infection 11 17.7
Staphylococcus haemolyticus 7 11.29
Staphylococcus epidermididis 4 6.45
Staphylococcus aureus 2 3.23
Methicillin-resistant Staphylococcus aureus 4 6.45
Varicella-zoster virus 1 1.61
Herpes simplex virus 2 3.23
Coxsackie group B virus 6 9.68
Adenovirus 5 8.06
Cytomegalovirus 1 1.61
Human herpesvirus type IV (EBV) 2 3.23
Respiratory syncytial virus 2 3.23
Hepatitis B virus 2 3.23
Hepatitis C virus 1 1.61
Mycoplasma pneumoniae 6 9.68
Divergent tuberculosis bacillus 2 3.23

EBV- Epstein-Barr virus.

In order to explore the related factors for concomitant systemic infections in EP, we involved the indicators of more than 90 cases in the infected and the non-infected groups into the unconditional logistic regression analysis, including demography, medical history characteristics, and some baseline laboratory investigations. For all variables included in the regression analysis, the regression model automatically excluded patients who are missing any one variable. Among the 105 EP, 10 EP patients were excluded, and 95 patients were included in the regression analysis, of which 56 were infected and 39 were not. The final results showed that joint pain and/or pustule symptoms, smoking history, hyperglycaemia, and hypoproteinaemia were related factors for EP combined with systemic infection. The results of univariate and multivariable analysis of EP combined systemic infection are shown in Table 2. The analysis method used Forward LR.

Table 2: Univariate and multivariable analysis of systemic infection in patients with erythrodermic psoriasis.
Factor
Univariate analysis
Multivariable analysis
OR 95% CI P OR 95% CI P
Gender Man 1
Woman 2.829 1.080–7.405 0.034
Age (years) <60 1
≥60 0.720 0.329–1.577 0.412
Admission season Non-seasonal 1
Seasonal 2.58 1.023–6.506 0.045
History of smoking not 1
Yes 2.937 1.066–8.092 0.037 7.641 1.716–34.025 0.008
Arthralgia/pustules not 1
Yes 2.937 1.066–8.092 0.037 5.140 1.200–22.011 0.027
Number of comorbidities <3 1
≥3 2.634 1.003–6.917 0.049
Conscious symptoms Light/None 1
Itching 0.689 0.284–1.674 0.411
Pain 1.063 0.309–3.659 0.923
Blood glucose Not high 1
Elevated 4.800 1.292-17.839 0.019 7.290 1.293–41.109 0.024
Hypoproteina-emia Not 1
Yes 10.543 3.996-27.817 <0.001 19.234 5.380–68.761 <0.001
Psoriasis course 0.979 0.954–1.005 0.120
Erythroderma course 1.000 0.986–1.014 0.987

OR: odds ratio, CI: confidence interval.

By comparing the data differences between the EP infected group and non-infected group, we detected inter-group differences pertaining to the following laboratory characteristics: Neutrophil Count (NEUT), C-Reactive Protein (CRP), Systemic Immune-inflammation Index (SII), Alpha-1 Acidic Glycoprotein (AAG), D-Dimer (D-D), N-Terminal pro-B-type Natriuretic Peptide (NT-ProBNP), Aspartate Transaminase (AST), Alanine Transaminase (ALT), Glutamyl Transferase (GGT), Albumin (ALB), Cholinesterase (CHE), Serum potassium (K), Serum phosphorus (P), Serum sodium (Na), Serum chloride (Cl), Serum calcium (Ca), Blood glucose (GLU), Low-Density Lipoprotein cholesterol (LDL-c), Total Cholesterol (TC). The remaining indicators were comparable, as shown in Table 3.

Table 3: Laboratory tests of blood samples of patients with erythrodermic psoriasis.
Variable Infection group Non-infected group Statistic P
Neutrophil count (10^9/L) 7.6 (6.5) 4.6 (2.7) −4.657 <0.001**
Lymphocyte count (10^9/L) 1.5 (1.0) 1.6 (0.8) −1.300 0.193
Platelet count (10^9/L) 293.8±116.5 276.1±87.9 0.837 0.404
C-reactive protein (mg/L) 60.6 (96.2) 12.5 (26.8) −4.511 <0.001**
Systemic immune-inflammation index (10^9/L) 1340.0 (1629.8) 739.3 (501.4) −4.415 <0.001**
Alpha-1 acidic glycoprotein (mg/dl) 148.0 (111.7) 121.0 (60.9) −2.142 0.032*
D-Dimer (μg/mL) 2.3 (3.8) 1.1 (1.7) −2.360 0.016*
N-Terminal pro-B-type natriuretic peptide (pg/mL) 614.8 (1412.0) 183.0 (470.9) −2.022 0.043*
Albumin (g/L) 31.6±5.9 37.1±4.4 −5.439 <0.001**
Cholinesterase (U/L) 4731.5±1988.8 6221.3±2056.5 −3.659 <0.001**
Aspartate transaminase normal 45 (73.8) 36 (90.0) 4.007 0.045*
abnormal 16 (26.2) 4 (10.0)
Alanine transaminase normal 47 (77.0) 38 (92.7) 4.315 0.038*
abnormal 14 (23.0) 3 (7.3)
Glutamyl transferase normal 47 (77.0) 38 (95.0) 5.839 0.016*
abnormal 14 (23.0) 2 (5.0)
Serum potassium normal 47 (75.8) 39 (95.1) 6.682 0.010*
abnormal 15 (24.2) 2 (4.9)
Serum sodium normal 42 (67.7) 39 (95.1) 11.015 0.001**
abnormal 20 (32.3) 2 (4.9)
Serum chloride normal 41 (66.1) 41 (100.0) 17.444 <0.001**
abnormal 21 (33.9) 0 (0.0)
Serum calcium normal 27 (43.5) 28 (68.3) 6.072 0.014*
abnormal 35 (56.5) 13 (31.7)
Serum phosphorus normal 45 (73.8) 37 (90.2) 4.221 0.040*
abnormal 16 (26.2) 4 (9.8)
Low density lipoprotein cholesterol normal 32a (62.7) 29a (93.5) 10.501 0.001**
elevated 4a (7.8) 2a (6.5)
lower 15b (29.4) 0b (0.0)
Total Cholesterol normal 37a (67.3) 31a (91.2) 6.881 0.009*
elevated 2a,b (3.6) 1a,b (2.9)
lower 16b (29.1) 2b (5.9)
Blood glucose not elevated 40 (71.4) 36 (92.3) 6.264 0.012*
elevated 16 (28.6) 3 (7.7)

Platelet count, albumin and cholinesterase conform to the normal distribution and the t-tests were used. The remaining quantitative indicators do not conform to the normal distribution and the non-parametric test is used. The chi-square test is used for categorical variables and the non-parametric test is used for graded variables. Low density lipoprotein cholesterol and Total cholesterol are further compared in pairs and the same letter subscript indicates that there is no difference between the two pairs. * indicates a statistical difference in distribution between the two groups. ** indicates a significant difference.

The ROC curve was used to verify the diagnostic performance of some laboratory investigations to indicate infection in EP. The Jordon index (sensitivity + specificity -1) corresponding to each cut-off value was calculated and the point with the largest Jordon index was considered the best cut-off value.

Scatter plots, the ROC curve, and its parameters including CRP, SII, AAG, NT-ProBNP, ALB, CHE, and TC are shown in Figures 12. Table 4 shows the comparison of P-values before and after adjusting for age, EP course, and body mass index using covariance for each biomarker. Through the accuracy test of the single index for the diagnosis of EP infection, we found that the comprehensive diagnostic values of CRP, SII, and ALB were high and the AUCs were greater than 0.75. TC has high specificity for diagnosing infection. The four indexes are included in multivariate regression analysis to obtain its joint predictive value and its diagnostic performance is tested.. As shown by the red curve in Figure 1, the AUC for the diagnosis of EP infection with the joint predictive value is 0.903 which is greater than any single indicator and the best cut-off value is 0.6895 with sensitivity of 79.6% and specificity of 96.15%. This regression predictive value is a relatively ideal diagnostic index, but more sample verification is needed.

Scatter Plots of Lab Test Values in Infected vs. Non-infected Erythrodermic Psoriasis Patients. Blue dots (infected) and red dots (non-infected) indicate C-reactive protein values. Dotted line at 40.9 denotes optimal cut-off; above this, infected individuals dominate.
Figure 1a:
Scatter Plots of Lab Test Values in Infected vs. Non-infected Erythrodermic Psoriasis Patients. Blue dots (infected) and red dots (non-infected) indicate C-reactive protein values. Dotted line at 40.9 denotes optimal cut-off; above this, infected individuals dominate.
Scatter Plots of Lab Test Values in Infected vs. Non-infected Erythrodermic Psoriasis Patients. Blue dots (infected) and red dots (non-infected) indicate systemic immune-inflammation index values. Dotted line at 926.9 denotes optimal cut-off; above this, infected individuals dominate.
Figure 1b:
Scatter Plots of Lab Test Values in Infected vs. Non-infected Erythrodermic Psoriasis Patients. Blue dots (infected) and red dots (non-infected) indicate systemic immune-inflammation index values. Dotted line at 926.9 denotes optimal cut-off; above this, infected individuals dominate.
Scatter Plots of Lab Test Values in Infected vs. Non-infected Erythrodermic Psoriasis Patients. Blue dots (infected) and red dots (non-infected) indicate albumin values. Dotted line at 33.45 denotes optimal cut-off; below this, infected individuals dominate.
Figure 1c:
Scatter Plots of Lab Test Values in Infected vs. Non-infected Erythrodermic Psoriasis Patients. Blue dots (infected) and red dots (non-infected) indicate albumin values. Dotted line at 33.45 denotes optimal cut-off; below this, infected individuals dominate.
Scatter Plots of Lab Test Values in Infected vs. Non-infected Erythrodermic Psoriasis Patients. Blue dots (infected) and red dots (non-infected) indicate cholinesterase values. Dotted line at 5406 denotes optimal cut-off; below this, infected individuals dominate.
Figure 1d:
Scatter Plots of Lab Test Values in Infected vs. Non-infected Erythrodermic Psoriasis Patients. Blue dots (infected) and red dots (non-infected) indicate cholinesterase values. Dotted line at 5406 denotes optimal cut-off; below this, infected individuals dominate.
Scatter Plots of Lab Test Values in Infected vs. Non-infected Erythrodermic Psoriasis Patients. Blue dots (infected) and red dots (non-infected) indicate N-terminal pro-B-type natriuretic peptide values. Dotted line at 526.5 denotes optimal cut-off; above this, infected individuals dominate.
Figure 1e:
Scatter Plots of Lab Test Values in Infected vs. Non-infected Erythrodermic Psoriasis Patients. Blue dots (infected) and red dots (non-infected) indicate N-terminal pro-B-type natriuretic peptide values. Dotted line at 526.5 denotes optimal cut-off; above this, infected individuals dominate.
Scatter Plots of Lab Test Values in Infected vs. Non-infected Erythrodermic Psoriasis Patients. Blue dots (infected) and red dots (non-infected) indicate alpha-1 acidic glycoprotein values. Dotted line at 169 denotes optimal cut-off; above this, infected individuals dominate.
Figure 1f:
Scatter Plots of Lab Test Values in Infected vs. Non-infected Erythrodermic Psoriasis Patients. Blue dots (infected) and red dots (non-infected) indicate alpha-1 acidic glycoprotein values. Dotted line at 169 denotes optimal cut-off; above this, infected individuals dominate.
Scatter Plots of Lab Test Values in Infected vs. Non-infected Erythrodermic Psoriasis Patients. Blue dots (infected) and red dots (non-infected) indicate total cholesterol values. Dotted line at 3.295 denotes optimal cut-off; below this, infected individuals dominate.
Figure 1g:
Scatter Plots of Lab Test Values in Infected vs. Non-infected Erythrodermic Psoriasis Patients. Blue dots (infected) and red dots (non-infected) indicate total cholesterol values. Dotted line at 3.295 denotes optimal cut-off; below this, infected individuals dominate.
Scatter Plots of Lab Test Values in Infected vs. Non-infected Erythrodermic Psoriasis Patients. Blue dots (infected) and red dots (non-infected) indicate regression predictive value of CRP, SII, ALB and TC, which abbreviated as prediction. Dotted line at 0.6895 denotes optimal cut-off; above this, infected individuals dominate.
Figure 1h:
Scatter Plots of Lab Test Values in Infected vs. Non-infected Erythrodermic Psoriasis Patients. Blue dots (infected) and red dots (non-infected) indicate regression predictive value of CRP, SII, ALB and TC, which abbreviated as prediction. Dotted line at 0.6895 denotes optimal cut-off; above this, infected individuals dominate.
ROC curves of laboratory indicators diagnosis of EP is complicated with infection. The yellow curve shows the ROC curve of CRP for the diagnosis of EP infection. The sensitivity is 64.7%, specificity is 84.8%, the area under the curve (AUC) is 0.793 and the 95% confidence interval (CI) is (0.698, 0.887). The orange curve shows the ROC curve of ALB. The sensitivity is 67.2%, specificity is 87.5%, AUC is 0.771, and 95%CI is (0.679, 0.862). The green curve shows the ROC curve of SII. The sensitivity is 72.9%, specificity is 72.1%, AUC is 0.757, and 95% CI is (0.664, 0.850). The dark green curve shows the ROC curve of CHE. The sensitivity is 65.6%, specificity is 70.7%, AUC is 0.708, and 95%CI is (0.607, 0.809). The blue curve shows the ROC curve of AAG. The sensitivity is 43.2%, specificity is 100%, AUC is 0.683, and 95%CI is (0.544, 0.822). The purple curve shows the ROC curve of NT-proBNP. The sensitivity is 54.3%, specificity is 80.0%, AUC is 0.682, and 95%CI is (0.520, 0.844). The pink curve shows the ROC curve of TC. The sensitivity is 40.0%, specificity is 94.1%, AUC is 0.640, and 95%CI is (0.527, 0.753). The red curve shows the ROC curve of prediction, which referred to the regression predictive value of CRP, SII, ALB, and TC. The sensitivity is 79.6%, specificity is 96.15%, AUC is 0.903, and 95%CI is (0.833, 0.973). The AUC is greater than any single indicator’s performance. (CRP: C-Reactive Protein, ALB: Albumin, SII: Systemic Immune-inflammation Index, CHE: Cholinesterase, AAG: Alpha-1 Acidic Glycoprotein, NT-proBNP: N-Terminal pro-B-type Natriuretic Peptide, TC: Total Cholesterol.)
Figure 2:
ROC curves of laboratory indicators diagnosis of EP is complicated with infection. The yellow curve shows the ROC curve of CRP for the diagnosis of EP infection. The sensitivity is 64.7%, specificity is 84.8%, the area under the curve (AUC) is 0.793 and the 95% confidence interval (CI) is (0.698, 0.887). The orange curve shows the ROC curve of ALB. The sensitivity is 67.2%, specificity is 87.5%, AUC is 0.771, and 95%CI is (0.679, 0.862). The green curve shows the ROC curve of SII. The sensitivity is 72.9%, specificity is 72.1%, AUC is 0.757, and 95% CI is (0.664, 0.850). The dark green curve shows the ROC curve of CHE. The sensitivity is 65.6%, specificity is 70.7%, AUC is 0.708, and 95%CI is (0.607, 0.809). The blue curve shows the ROC curve of AAG. The sensitivity is 43.2%, specificity is 100%, AUC is 0.683, and 95%CI is (0.544, 0.822). The purple curve shows the ROC curve of NT-proBNP. The sensitivity is 54.3%, specificity is 80.0%, AUC is 0.682, and 95%CI is (0.520, 0.844). The pink curve shows the ROC curve of TC. The sensitivity is 40.0%, specificity is 94.1%, AUC is 0.640, and 95%CI is (0.527, 0.753). The red curve shows the ROC curve of prediction, which referred to the regression predictive value of CRP, SII, ALB, and TC. The sensitivity is 79.6%, specificity is 96.15%, AUC is 0.903, and 95%CI is (0.833, 0.973). The AUC is greater than any single indicator’s performance. (CRP: C-Reactive Protein, ALB: Albumin, SII: Systemic Immune-inflammation Index, CHE: Cholinesterase, AAG: Alpha-1 Acidic Glycoprotein, NT-proBNP: N-Terminal pro-B-type Natriuretic Peptide, TC: Total Cholesterol.)
Table 4: P-values before and after adjusted using covariance for each biomarker
Indicators P P’
CRP <0.001 <0.001
SII <0.001 0.003
TC 0.027 0.041
CHE <0.001 0.005
ALB <0.001 <0.001
NT-proBNP 0.043 0.830
AAG 0.032 0.294
The regression predictive value <0.001 <0.001

P’ is the P-value adjusted for age, EP course and body mass index using covariance analysis. CRP: C-Reactive Protein, ALB: Albumin, SII: Systemic Immune-inflammation Index, CHE: Cholinesterase, AAG: Alpha-1 Acidic Glycoprotein, NT-proBNP: N-Terminal pro-B-type Natriuretic Peptide, TC: Total Cholesterol.

A total of 105 cases of EP were included in this retrospective analysis with a total infection rate of 45.3%, The infection rate of EP patients was higher in women compared to men, consistent with results of Zaredar N and Yiu ZZN.3,4

Although previous studies have shown that EP disease itself leads to an increase in inflammatory markers such as CRP,5,6 our study found that their rise indicates EP is complicated with infection, and new best cut-off values for CRP were obtained. We also found that SII, ALB, CHE, TC, AAG, and NT ProBNP may indicate concomitant infection in EP patients, and we explored their comprehensive diagnostic values, sensitivity, specificity, and best cut-off values. Notably, the regression predictive values of CRP, SII, ALB, and TC may be better indicators of infection in EP. However, we conducted a preliminary study with a small to medium-sized sample size, and further verification is needed in the future.

Ethical approval

The research/study was approved by the Institutional Review Board at The Medical Ethics Committee of Xuzhou Medical University Affiliated Hospital, number XYFY2022-KL454-01, dated 2023-01-06.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

Use of artificial intelligence (AI)-assisted technology for manuscript preparation

The authors confirm that there was no use of artificial intelligence (AI)-assisted technology for assisting in the writing or editing of the manuscript and no images were manipulated using AI.

Reference

  1. , . Updates on the treatment of erythrodermic psoriasis. Psoriasis (Auckland, N.Z.). 2021;11:59-73.
    [CrossRef] [PubMed] [PubMed Central] [Google Scholar]
  2. , , , . Prognosis after hospitalization for erythroderma. Acta Dermato Venereologica. 2016;96:959-62.
    [CrossRef] [PubMed] [Google Scholar]
  3. , , , , , , et al. Infections in hospitalized patients with psoriasis in a skin referral hospital. Dermatol Pract Concept. 2023;13:e202302.
    [CrossRef] [PubMed] [PubMed Central] [Google Scholar]
  4. , , , , , , et al. Development and validation of a multivariable risk prediction model for serious infection in patients with psoriasis receiving systemic therapy. Br J Dermatol. 2019;180:894-901.
    [CrossRef] [PubMed] [PubMed Central] [Google Scholar]
  5. , , , , , , et al. C-reactive protein, chemerin, fetuin-A and osteopontin as predictors of cardiovascular risks in persons with psoriasis vulgaris. Physiol Res. 2021;70:383-91.
    [CrossRef] [PubMed] [PubMed Central] [Google Scholar]
  6. , , . Pathophysiology of generalized pustular psoriasis. Exp Dermatol. 2023;32:1194-203.
    [CrossRef] [PubMed] [PubMed Central] [Google Scholar]

Fulltext Views
1,186

PDF downloads
1,027
View/Download PDF
Download Citations
BibTeX
RIS
Show Sections